Pijp schreef op 1 augustus 2023 15:15:
Pharming Group NV is expected to show a rise in quarterly revenue when it reports results on August 3.
The Leiden Zuid-holland-based company is expected to report a 5.1% increase in revenue to $52.78 million from $50.2 million a year ago, according to the mean estimate from 2 analysts, based on Refinitiv data.
?Refinitiv's mean analyst estimate for Pharming Group NV is for a loss of 1 cent per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months. ?
Wall Street's median 12-month price target for Pharming Group NV is €1.78?, below? its last closing price of $12.00. ???
This summary was machine generated August 1 at 11:23 GMT. All figures in US dollars unless otherwise stated.
Keywords: PHARMING GROUP RESULTS/PREVIEW
Bron DeGiro